SCHEMBL192940

SCHEMBL192940

O=Cc1ccccc1-n1cncn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2A6 P11509 1/20 0.40
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
FBP1 P09467 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30855444 0.83 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL10955823 0.82 LMNA (0.40) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL2513072 0.80 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL13351490 0.79 LMNA (0.38) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL15777237 0.79 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL29355282 0.79 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL13318675 0.78 LMNA (0.38) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL616961 0.77 CRHBP (0.47) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL1957022 0.77 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL1956908 0.77 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
CN-118459510-A Ruthenium polypyridine complex with azole skeleton structure, and preparation method and application thereof 江西科技师范大学 2024-08-09 CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2305629-A1 THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE Tokyo Institute of Technology (JP) 2011-04-06 EP disclosed
CN-101970432-A fungicidal heterocyclic compounds DU PONT 2011-02-09 CN disclosed
CN-101925598-A Fungicidal amides DU PONT 2010-12-22 CN disclosed
US-20100292275-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-11-18 US disclosed
US-20100286147-A1 FUNGICIDAL AMIDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2010-11-11 US disclosed
EP-2037947-A2 MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2009-03-25 EP disclosed
US-20080181868-A1 MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-07-31 US disclosed
WO-2007143694-A2 MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2007-12-13 WO disclosed
US-20070281884-A1 Macrocyclic oximyl hepatitis C protease inhibitors ENANTA PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281885-A1 MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP ALDH1A1 312/4885KDM4E 2437/4885SMN1; SMN2 3418/4885
US-20080181868-A1 MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS HCCS, CPN1, HPN ALDH1A1 938/4885KDM4E 893/4885SMN1; SMN2 3272/4885
US-20070281885-A1 MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS HCCS, CPN1, HPN ALDH1A1 938/4885KDM4E 893/4885SMN1; SMN2 3272/4885
US-20100286147-A1 FUNGICIDAL AMIDES NAT1, NOX1, CBR1 ALDH1A1 595/4885KDM4E 904/4885SMN1; SMN2 3057/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ALDH1A1 587/4885KDM4E 3565/4885SMN1; SMN2 3345/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP ALDH1A1 312/4885KDM4E 2437/4885SMN1; SMN2 3418/4885
US-20100292275-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS CYP1B1, CBR1, NOX1 ALDH1A1 506/4885KDM4E 1822/4885SMN1; SMN2 2293/4885
US-20070281884-A1 Macrocyclic oximyl hepatitis C protease inhibitors HCCS, HPN, CYP3A4 ALDH1A1 907/4885KDM4E 769/4885SMN1; SMN2 3218/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP ALDH1A1 312/4885KDM4E 2437/4885SMN1; SMN2 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.